Imagina Biotechnology
Creates value from scientific discovery to deliver smarter and higher quality solutions for better gene expression analysis.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
N/A | Grant | ||
| Total Funding | 000k | ||
| EUR | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 152 % | 479 % | 175 % | 102 % | 137 % | 144 % | 24 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (760 %) | (102 %) | 111 % | (40 %) | - | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (1640 %) | (395 %) | 5 % | (91 %) | (93 %) | (63 %) | (35 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Immagina Biotech specializes in developing cutting-edge technologies for ribosome profiling and translational studies. The company serves academic researchers, pharmaceutical companies, and biotech firms by providing unique tools and kits that enable detailed analysis of ribosome function and the regulation of translation. Operating in the biotechnology market, Immagina Biotech's business model revolves around the sale of specialized products and services designed to facilitate advanced research in molecular biology. Revenue is generated through direct sales of their proprietary kits and modules, as well as through grants and collaborations with research institutions.
Keywords: ribosome profiling, translational studies, molecular biology, biotech tools, academic research, pharmaceutical, biotech firms, specialized kits, proprietary technology, research grants.